AQST
Price
$3.41
Change
+$0.23 (+7.23%)
Updated
Jun 4 closing price
Capitalization
383.26M
68 days until earnings call
SUPN
Price
$32.30
Change
+$0.07 (+0.22%)
Updated
Jun 4 closing price
Capitalization
1.84B
56 days until earnings call
Interact to see
Advertisement

AQST vs SUPN

Header iconAQST vs SUPN Comparison
Open Charts AQST vs SUPNBanner chart's image
Aquestive Therapeutics
Price$3.41
Change+$0.23 (+7.23%)
Volume$3.39M
Capitalization383.26M
Supernus Pharmaceuticals
Price$32.30
Change+$0.07 (+0.22%)
Volume$367.98K
Capitalization1.84B
AQST vs SUPN Comparison Chart
Loading...
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AQST vs. SUPN commentary
Jun 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AQST is a StrongBuy and SUPN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 05, 2025
Stock price -- (AQST: $3.41 vs. SUPN: $32.30)
Brand notoriety: AQST and SUPN are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: AQST: 226% vs. SUPN: 76%
Market capitalization -- AQST: $383.26M vs. SUPN: $1.84B
AQST [@Pharmaceuticals: Other] is valued at $383.26M. SUPN’s [@Pharmaceuticals: Other] market capitalization is $1.84B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AQST’s FA Score shows that 0 FA rating(s) are green whileSUPN’s FA Score has 0 green FA rating(s).

  • AQST’s FA Score: 0 green, 5 red.
  • SUPN’s FA Score: 0 green, 5 red.
According to our system of comparison, AQST is a better buy in the long-term than SUPN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AQST’s TA Score shows that 4 TA indicator(s) are bullish while SUPN’s TA Score has 4 bullish TA indicator(s).

  • AQST’s TA Score: 4 bullish, 5 bearish.
  • SUPN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both AQST and SUPN are a bad buy in the short-term.

Price Growth

AQST (@Pharmaceuticals: Other) experienced а +33.73% price change this week, while SUPN (@Pharmaceuticals: Other) price change was +0.47% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +73.69%. For the same industry, the average monthly price growth was +15.08%, and the average quarterly price growth was +62.67%.

Reported Earning Dates

AQST is expected to report earnings on Aug 12, 2025.

SUPN is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+73.69% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SUPN($1.84B) has a higher market cap than AQST($383M). AQST YTD gains are higher at: -4.213 vs. SUPN (-10.675). SUPN has higher annual earnings (EBITDA): 90M vs. AQST (1.18M). SUPN has more cash in the bank: 255M vs. AQST (23.9M). AQST has less debt than SUPN: AQST (33.3M) vs SUPN (41.5M). SUPN has higher revenues than AQST: SUPN (608M) vs AQST (50.6M).
AQSTSUPNAQST / SUPN
Capitalization383M1.84B21%
EBITDA1.18M90M1%
Gain YTD-4.213-10.67539%
P/E RatioN/A1677.00-
Revenue50.6M608M8%
Total Cash23.9M255M9%
Total Debt33.3M41.5M80%
FUNDAMENTALS RATINGS
AQST vs SUPN: Fundamental Ratings
AQST
SUPN
OUTLOOK RATING
1..100
1920
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
10062
SMR RATING
1..100
10080
PRICE GROWTH RATING
1..100
5357
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AQST's Valuation (39) in the Pharmaceuticals Major industry is somewhat better than the same rating for SUPN (72) in the Pharmaceuticals Other industry. This means that AQST’s stock grew somewhat faster than SUPN’s over the last 12 months.

SUPN's Profit vs Risk Rating (62) in the Pharmaceuticals Other industry is somewhat better than the same rating for AQST (100) in the Pharmaceuticals Major industry. This means that SUPN’s stock grew somewhat faster than AQST’s over the last 12 months.

SUPN's SMR Rating (80) in the Pharmaceuticals Other industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that SUPN’s stock grew similarly to AQST’s over the last 12 months.

AQST's Price Growth Rating (53) in the Pharmaceuticals Major industry is in the same range as SUPN (57) in the Pharmaceuticals Other industry. This means that AQST’s stock grew similarly to SUPN’s over the last 12 months.

AQST's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as SUPN (100) in the Pharmaceuticals Other industry. This means that AQST’s stock grew similarly to SUPN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AQSTSUPN
RSI
ODDS (%)
Bearish Trend 1 day ago
80%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
73%
Momentum
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
68%
MACD
ODDS (%)
Bullish Trend 1 day ago
69%
Bearish Trend 1 day ago
65%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
72%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
69%
Advances
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
73%
Declines
ODDS (%)
Bearish Trend 15 days ago
89%
Bearish Trend 7 days ago
67%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
71%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ESMYX16.89N/A
N/A
Invesco EQV Euro Small Company Y
BPTRX198.40N/A
N/A
Baron Partners Retail
UPUPX10.54N/A
N/A
Upright Growth
JFARX36.09N/A
N/A
JHancock Fundamental All Cap Core R4
GMNPX39.04N/A
N/A
Goldman Sachs MLP Energy Infras P

SUPN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SUPN has been loosely correlated with DVAX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if SUPN jumps, then DVAX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SUPN
1D Price
Change %
SUPN100%
+0.22%
DVAX - SUPN
34%
Loosely correlated
-1.20%
SNDL - SUPN
27%
Poorly correlated
+0.78%
ACET - SUPN
27%
Poorly correlated
+1.54%
AQST - SUPN
27%
Poorly correlated
+7.23%
ESPR - SUPN
26%
Poorly correlated
+6.67%
More